Literature DB >> 1867949

Desirability of immediate surgical standby for coronary angioplasty.

R D Levy1, D H Bennett, N H Brooks.   

Abstract

OBJECTIVE: To assess the value of emergency surgical standby for percutaneous transluminal coronary angioplasty.
DESIGN: Retrospective review of the major complications of coronary angioplasty in a regional cardiac centre.
SETTING: All angioplasties were performed in the cardiac catheterisation laboratory of Wythenshawe Hospital with surgical standby in an adjoining operating theatre. PATIENTS: 1262 vessels were dilated in 1032 patients (mean age 53 years) between 1984 and 1989. MAIN OUTCOME MEASURES: In-hospital mortality from emergency surgical revascularisation after angioplasty; the rate of myocardial infarction and overall morbidity.
RESULTS: Coronary angioplasty achieved primary success in 90% of cases. Thirty eight (3.7%) patients (five women (mean age 55.8) and 33 men (mean age 53.0] were referred for urgent surgical revascularisation--36 direct to operation and two within 24 hours. All patients survived surgery. Five of the 38 had had a previous angioplasty to the same vessel and one had had previous coronary artery grafts. Four of the 38 had an angioplasty for unstable angina. Eighteen had single, 13 double, and seven triple vessel coronary artery disease. The target vessel was the left anterior descending in 25, right coronary artery in nine, circumflex in three, and the left anterior descending and circumflex coronary arteries in one. Five required external cardiac massage on the way to the operating theatre; two of them had a left main stem occlusion. Four internal mammary artery and 60 reversed saphenous vein grafts were implanted (1.6 per patient). Complete revascularisation was achieved in 36 (94.7%) patients. Q wave myocardial infarction occurred in six (15.8%). The final outcome was: none dead, three patients with angina, one late death, one cerebrovascular accident, one late operation for a new left anterior descending lesion, two patients on diuretics with or without an angiotensin converting enzyme inhibitor. One orthotopic transplant was performed in a patient in whom cardiogenic shock developed after the left anterior descending coronary artery became occluded 72 hours after angioplasty.
CONCLUSION: There was no surgical mortality and low morbidity among patients for whom immediate surgical cover was requested.

Entities:  

Mesh:

Year:  1991        PMID: 1867949      PMCID: PMC1024493          DOI: 10.1136/hrt.65.2.68

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  13 in total

1.  Acute myocardial ischaemia and cardiogenic shock after percutaneous transluminal coronary angioplasty; risk factors for and results of emergency coronary bypass.

Authors:  J J Bredée; J H Bavinck; E Berreklouw; H J Bonnier; C Van Doorn; M I el Gamal; P N Hendel; Y A Mashhour; H R Michels; T H Relik
Journal:  Eur Heart J       Date:  1989-12       Impact factor: 29.983

2.  Does angioplasty need on site surgical cover? A surgeon's view.

Authors:  D J Parker
Journal:  Br Heart J       Date:  1990-07

3.  Does angioplasty need on site surgical cover? A physician's view.

Authors:  T R Shaw
Journal:  Br Heart J       Date:  1990-07

4.  Management of acute coronary occlusion during percutaneous transluminal coronary angioplasty: experience of complications in a hospital without on site facilities for cardiac surgery.

Authors:  S G Richardson; P Morton; J G Murtagh; D B O'Keeffe; P Murphy; M E Scott
Journal:  BMJ       Date:  1990-02-10

5.  Transluminal intracoronary reperfusion catheter: a device to maintain coronary perfusion between failed coronary angioplasty and emergency coronary bypass surgery.

Authors:  T Hinohara; J B Simpson; H R Phillips; R S Stack
Journal:  J Am Coll Cardiol       Date:  1988-05       Impact factor: 24.094

6.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).

Authors:  T J Ryan; D P Faxon; R M Gunnar; J W Kennedy; S B King; F D Loop; K L Peterson; T J Reeves; D O Williams; W L Winters
Journal:  Circulation       Date:  1988-08       Impact factor: 29.690

7.  Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute.

Authors:  K M Kent; L G Bentivoglio; P C Block; M J Cowley; G Dorros; A J Gosselin; A Gruntzig; R K Myler; J Simpson; S H Stertzer; D O Williams; L Fisher; M J Gillespie; K Detre; S Kelsey; S M Mullin; M B Mock
Journal:  Am J Cardiol       Date:  1982-06       Impact factor: 2.778

8.  Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.

Authors:  B Rath; D H Bennett
Journal:  Br Heart J       Date:  1990-01

9.  Coronary artery bypass for unsuccessful percutaneous transluminal coronary angioplasty.

Authors:  G J Reul; D A Cooley; G L Hallman; J M Duncan; J J Livesay; O H Frazier; D A Ott; P Angelini; A Massumi; V S Mathur
Journal:  J Thorac Cardiovasc Surg       Date:  1984-11       Impact factor: 5.209

10.  Myocardial revascularization after failure of percutaneous transluminal coronary angioplasty.

Authors:  L C Pelletier; A Pardini; J Renkin; P R David; Y Hébert; M G Bourassa
Journal:  J Thorac Cardiovasc Surg       Date:  1985-08       Impact factor: 5.209

View more
  3 in total

1.  Surgical cover for percutaneous transluminal coronary angioplasty. The Council of the British Cardiovascular Intervention Society.

Authors: 
Journal:  Br Heart J       Date:  1992-09

2.  Emergency surgical revascularisation for coronary angioplasty complications.

Authors:  J A Carey; S W Davies; R Balcon; C Layton; P Magee; M T Rothman; A D Timmis; J E Wright; R K Walesby
Journal:  Br Heart J       Date:  1994-11

Review 3.  The invasive management of angina: issues for consumers and commissioners.

Authors:  D Gunnell; I Harvey; L Smith
Journal:  J Epidemiol Community Health       Date:  1995-08       Impact factor: 3.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.